Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive’s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
Catch up on CGTLive's coverage of the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19, 2023.
Etranacogene dezaparvovec (Hemgenix; CSL Behring) has been approved by the European Commission (EC) for the treatment of severe and moderately severe hemophilia B in adults without a history of Factor IX inhibitors.
The Secretary of the Department of Health and Human Services (HHS) has selected 3 new models by the Centers for Medicaid & Medicare Services for testing, 2 of which directly affect cell and gene therapies, to help lower costs and improve access to novel therapies.
Posoleucel (AlloVir) cell therapy has shown efficacy in treating patients with BK viremia who have received a kidney transplant in new data from a phase 2 trial (NCT04605484).
The Type B meeting will be focused on proposed changes to the ongoing phase 3 MASTERS-2 clinical trial (NCT03545607), which is evaluating MultiStem (invimestrocel).
The collaboration is focused on the development of allogeneic therapies for solid tumors.
The exclusive option and license agreement is focused on the potential use of novel beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell (iPSC) lines, which will be developed by Eterna Therapeutics, in therapies directed at central nervous system indications.
Nexcella has entered into a GMP manufacturing agreement with an undisclosed US manufacturer for the production of NXC-201, in preparation for submission an investigational new drug application to the FDA.
The patent covers the use of Allocetra in the prevention or treatment of cytokine release syndrome caused by CAR-T therapy, infection, and other sources.
Aera Therapeutics launched in February 2023 with the support of $193 million raised across Series A and Series B financing rounds.
Nanite will leverage its SAYER gene delivery platform with the goal of developing a delivery vehicle capable of efficiently passing through the blood-nerve barrier.